-$0.66 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter
Equities analysts predict that Epizyme, Inc. (NASDAQ:EPZM) will post earnings of ($0.66) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Epizyme’s earnings. The highest EPS estimate is ($0.57) and the lowest is ($0.75). Epizyme posted earnings per share of ($0.42) in the same quarter last year, which would suggest a negative year-over-year growth rate of 57.1%. The company is expected to report its next quarterly earnings report on Thursday, November 2nd.
On average, analysts expect that Epizyme will report full-year earnings of ($2.36) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.20). For the next year, analysts anticipate that the firm will report earnings of ($2.55) per share, with EPS estimates ranging from ($3.11) to ($2.18). Zacks’ EPS calculations are an average based on a survey of research firms that follow Epizyme.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.08. The firm had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.95 million. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. Epizyme’s quarterly revenue was up 2027.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.49) EPS.
Several brokerages recently issued reports on EPZM. Jefferies Group LLC initiated coverage on shares of Epizyme in a report on Wednesday. They set a “buy” rating and a $23.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Epizyme in a report on Monday, August 7th. Leerink Swann reissued an “outperform” rating and set a $28.00 target price (down from $31.00) on shares of Epizyme in a report on Wednesday, August 9th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday. Finally, Cann reissued a “buy” rating and set a $26.00 target price on shares of Epizyme in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Epizyme presently has a consensus rating of “Buy” and a consensus target price of $23.33.
Shares of Epizyme (NASDAQ:EPZM) opened at 18.70 on Friday. The stock’s 50 day moving average price is $15.50 and its 200 day moving average price is $15.25. The firm’s market cap is $1.09 billion. Epizyme has a 12-month low of $8.38 and a 12-month high of $19.60.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $15.68, for a total transaction of $235,200.00. Following the transaction, the insider now owns 22,228 shares in the company, valued at approximately $348,535.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average price of $15.25 per share, for a total transaction of $3,050,000.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at $91,500. The disclosure for this purchase can be found here. Insiders have sold a total of 48,024 shares of company stock worth $706,722 in the last quarter. 25.20% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC acquired a new position in Epizyme during the second quarter worth $9,726,000. The Manufacturers Life Insurance Company raised its holdings in Epizyme by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 1,068 shares during the last quarter. State Street Corp raised its holdings in Epizyme by 59.6% during the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after buying an additional 658,727 shares during the last quarter. Palo Alto Investors LLC raised its holdings in Epizyme by 18.9% during the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after buying an additional 907,245 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in Epizyme during the second quarter worth $215,000. Hedge funds and other institutional investors own 83.74% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “-$0.66 Earnings Per Share Expected for Epizyme, Inc. (EPZM) This Quarter” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/21/0-66-earnings-per-share-expected-for-epizyme-inc-epzm-this-quarter.html.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.